CD96/TACTILE (C110S), His, Human
| $390.00 | |
| Z04236-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $390.00 | |
| Z04236-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 54.63 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 100-130 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Anti-CD96 Antibody, hFc Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for CD96/TACTILE (C110S), His, Human, His Tag with the EC50 of 28.7ng/ml determined by ELISA. »
The purity of CD96/TACTILE (C110S), His, Human is greater than 95% as determined by SEC-HPLC. »
CD96/TACTILE (C110S), His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development. |
| Synonyms | CD96 molecule; CD96; DKFZp667E2122; TACTILE |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.